CEP-1347 was originally developed as a JNK pathway inhibitor to prevent neuronal death in Parkinson’s disease (PD) and was expected to become a PD treatment; however, its efficacy was not demonstrated in clinical trials. This evidence concerns the gene MAPK8 and Parkinson disease.